SuperTruth × imaware × BioPhy
Building adaptive baselines for deeper insights
Most platforms treat lab data as static snapshots. BioPhy, an AI-driven pharmatech company, worked with imaware and SuperTruth to test a living baseline instead: lab biomarkers, device inputs, and demographics as one evolving record that gets more precise with every layer added.
BioPhy is now Intrinsic BioPhy, part of Intrinsic Clinical Systems.
Source: the imaware case study →
The challenge
Lab-based biomarker data, device data, and demographic inputs lived apart. Connecting them at scale is what unlocks personalized, one-to-one health insights, and nobody had a repeatable way to do it.
The goal
Explore how a modular, evolving baseline could support dynamic biomarker analysis: accurate, personalized recommendations, so people can proactively manage their health.
The solution
imaware
Structured, anonymized baseline lab results for individuals via validated at-home collection and clinical lab integration.
SuperTruth
Ingested the lab results into a live, query-ready data layer, with contextual enrichment that becomes more precise over time.
BioPhy
Analytic capability with scientific research and rigor, testing how added data fields improve health summaries and reveal deeper insights.
Results
Incremental biomarker additions integrated successfully and changed recommendation outcomes: the baseline adapts instead of ossifying.
The infrastructure accepts new variables post-launch without disrupting the user experience.
The analysis found meaningful correlations between biomarker combinations and self-reported health inputs.
A demonstrated path to scalable interpretation, supporting more personalized recommendations with each layer of data.
Why it matters
A living baseline model evolves with added biomarkers and contextual data, unlocking more robust interpretation with each layer. That means faster insights for digital health platforms, more relevant guidance for their customers, and a path to better trial design without starting over.
BioPhy was acquired by Intrinsic Clinical Systems and continues as Intrinsic BioPhy, applying its regulatory research engine to quality and compliance work across pharma.
Intrinsic BioPhy →The same imaware records behind this baseline power the flagship case study: 105,000 diagnostic records, analysis in two hours instead of three weeks.
